Karen L. Reckamp, MD, MS, professor of medication, director, Division of Medical Oncology and Lung Institute, Cedars-Sinai Medical Middle, affiliate director, Medical Analysis, Cedars-Sinai Samuel Oschin Complete Most cancers Institute, discusses the position of amivantamab-vmjw (Rybrevant) within the remedy of sufferers with non–small cell lung most cancers (NSCLC) harboring EGFR exon 20 insertion mutations.
On March 1, 2024, the FDA authorised amivantamab plus carboplatin and pemetrexed for the frontline remedy of sufferers with domestically superior or metastatic NSCLC harboring EGFR exon 20 insertion mutations, as detected by an FDA-approved take a look at. The agent additionally acquired accelerated approval in Could 2021 as monotherapy for the remedy of grownup sufferers with domestically superior or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved take a look at, whose illness has progressed on or after platinum-based chemotherapy.
Within the section 3 PAPILLON research (NCT04538664), which supported the frontline approval of amivantamab plus chemotherapy, these handled with the mix (n = 153) skilled a median progression-free survival (PFS) of 11.4 months (95% CI, 9.8-13.7) vs 6.7 months (95% CI, 5.6-7.3) for these given chemotherapy alone (n = 155; HR, 0.40; 95% CI, 0.30-0.53; P < .0001).
Reckamp explains that amivantamab has develop into the first focused remedy thought-about for the remedy of sufferers with superior NSCLC harboring EGFR exon 20 insertion mutations. The EGFR- and MET-targeted antibody has demonstrated vital efficacy in beforehand handled sufferers, in addition to within the frontline setting when mixed with chemotherapy, she says. This dual-targeted method has resulted in notable enhancements in response charges and progression-free survival (PFS), she provides.
Reckamp emphasizes that the combination of amivantamab into remedy protocols represents a significant shift within the remedy of sufferers with EGFR exon 20–mutated NSCLC. With improved outcomes over chemotherapy alone, amivantamab affords a beneficial possibility for sufferers, doubtlessly main to raised general survival and illness management, she concludes.
